Increases Siemens’ industrial software total addressable market by $11 billion; aligns with strategic goal to accelerate customer innovation across industries
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Prior to joining Neuland, Deshmukh held several key positions at Cipla
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
Subscribe To Our Newsletter & Stay Updated
